Abstract
chelators hold great promise as disease-modifying drugs for Alzheimer’s therapy, and recent research efforts have focused on designing multi-target chelators with increased targeting and efficacy through rational drug design. In this review, we discuss our research studies on the rational design of new multi-target chelators with the potential not only to simultaneously modulate several disease-related targets, but also contain features designed to improve the BBB permeability, increase the brain targeting, and minimize potential side effects. These new chelators include neuroprotective chelators with brain selective monoamine oxidase (MAO) A/B inhibitory activity, acetylcholinesterase (AChE) inhibitors with site-activated chelating and neurogenesis activity, and AChE-MAO A/B inhibitors with siteactivated chelating and neurogenesis activity.
Keywords: AChE-MAO A/B inhibitors, HLA20, HLA20A, M30, M30D, multi-target chelators, site-activated, Alzheimer’s disease
Mini-Reviews in Medicinal Chemistry
Title:From Antioxidant Chelators to Site-Activated Multi-Target Chelators Targeting Hypoxia Inducing Factor, Beta-Amyloid, Acetylcholinesterase and Monoamine Oxidase A/B
Volume: 12 Issue: 5
Author(s): H. Zheng, M. Fridkin and M. B.H. Youdim
Affiliation:
Keywords: AChE-MAO A/B inhibitors, HLA20, HLA20A, M30, M30D, multi-target chelators, site-activated, Alzheimer’s disease
Abstract: chelators hold great promise as disease-modifying drugs for Alzheimer’s therapy, and recent research efforts have focused on designing multi-target chelators with increased targeting and efficacy through rational drug design. In this review, we discuss our research studies on the rational design of new multi-target chelators with the potential not only to simultaneously modulate several disease-related targets, but also contain features designed to improve the BBB permeability, increase the brain targeting, and minimize potential side effects. These new chelators include neuroprotective chelators with brain selective monoamine oxidase (MAO) A/B inhibitory activity, acetylcholinesterase (AChE) inhibitors with site-activated chelating and neurogenesis activity, and AChE-MAO A/B inhibitors with siteactivated chelating and neurogenesis activity.
Export Options
About this article
Cite this article as:
Zheng H., Fridkin M. and B.H. Youdim M., From Antioxidant Chelators to Site-Activated Multi-Target Chelators Targeting Hypoxia Inducing Factor, Beta-Amyloid, Acetylcholinesterase and Monoamine Oxidase A/B, Mini-Reviews in Medicinal Chemistry 2012; 12 (5) . https://dx.doi.org/10.2174/138955712800493898
DOI https://dx.doi.org/10.2174/138955712800493898 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives
Current Neuropharmacology GSK-3 Inhibitors: Recent Developments and Therapeutic Potential
Current Signal Transduction Therapy Patents in Cancer Stem Cells
Recent Patents on Biomarkers Approaches Targeting KV10.1 Open a Novel Window for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Ginkgo Biloba Extract (EGb 761) in Alzheimers Disease: Is there Any Evidence?
Current Alzheimer Research MYC-Mediated Synthetic Lethality for Treating Tumors
Current Cancer Drug Targets LGI1 Affects Survival of Neuroblastoma Cells by Inhibiting Signalling through Phosphoinositide 3-Kinase
Current Signal Transduction Therapy Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design Recent Achievement in the Synthesis of Benzo[b]furans
Current Organic Synthesis Vitamins B1, B2, B3 and B9 – Occurrence, Biosynthesis Pathways and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry MicroRNAs in Genetic Disease: Rethinking the Dosage
Current Gene Therapy Molecular Targeted Approaches for Treatment of Pancreatic Cancer
Current Pharmaceutical Design Regulators of the G1 Phase of the Cell Cycle and Neurogenesis
Central Nervous System Agents in Medicinal Chemistry P2X7 Receptors: Channels, Pores and More
CNS & Neurological Disorders - Drug Targets From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
Current Neuropharmacology Indolinones as Promising Scaffold as Kinase Inhibitors: A Review
Mini-Reviews in Medicinal Chemistry Functional Multipotency of Stem Cells: A Conceptual Review of Neurotrophic Factor-Based Evidence and Its Role in Translational Research
Current Neuropharmacology A Novel Marine Drug, SZ–685C, Induces Apoptosis of MMQ Pituitary Tumor Cells by Downregulating miR–200c
Current Medicinal Chemistry The Nrf2-ARE Pathway: A Valuable Therapeutic Target for the Treatment of Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued)